ClinicalTrials.gg
Active, not recruitingNCT06265220Updated Dec 10, 2025

AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus

A Phase 1 interventional study of AB-101 and Cyclophosphamide in Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV and Refractory Systemic Lupus Erythematosus, sponsored by Artiva Biotherapeutics, Inc.. Active, not recruiting at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-10.

Primary conditionLupus NephritisRegistry: Lupus Erythematosus, SystemicReclassifiedWhy we changed it
Registry
Lupus Erythematosus, Systemic — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lupus Nephritis
Why
  1. The study's listed conditions name Lupus Nephritis, a narrower term within Lupus Erythematosus, Systemic.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Artiva Biotherapeutics, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
51
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 114 studies in Lupus Nephritis with a site in United States — 39 open to participants now, 51 under way, 5 of them phase 3. Lupus Nephritis · United States.

Planned enrollment
50th of 100
51 · median 50
Started
2024
with 15 others
Phase 1
26 of 114
12 open now
Primary completion
2027-08
later than 10 of 49 live
Registered
76th of 114
by date

Among the 114 studies in Lupus Nephritis with a site in United States, this one is the 50th largest by planned enrollment of the 100 interventional ones that give a count, is one of 16 that started in 2024, is one of 26 in phase 1, reaches primary completion later than 10 of the 49 other live ones, and was the 76th registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

39 of the 114 studies in Lupus Nephritis with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Lupus Nephritis with a site in United States, or all of them as a file.
02

Study summary

AB-101 (also known as AlloNK) is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells. White blood cells are part of the immune system and NK cells are a type of white blood cell that is known to enhance the effect of monoclonal antibody therapies.

This clinical trial will enroll adult patients with lupus nephritis Class III or IV either with or without the presence of Class V who relapsed or did not respond to previous standard of care treatment approaches, or other forms of refractory systemic lupus erythematosus.

The primary objective is to assess the safety, tolerability and preliminary activity of AB-101 plus a B-cell depleting mAb (e.g., rituximab, obinutuzumab) after cyclophosphamide and fludarabine in adult subjects with relapsed/refractory lupus nephritis Class III or IV, with or without the presence of Class V, or other forms of refractory systemic lupus erythematosus.

Patients will be assigned to receive either AB-101 alone as monotherapy or in combination with a B-cell depleting mAb (e.g., rituximab, obinutuzumab). All patients will receive at least 1 treatment cycle of AB-101, followed by scheduled assessments of overall health and response status.

Patients may receive up to 2 cycles of treatment spaced 24 weeks apart.

03

Conditions studied

  • Lupus Nephritis - WHO Class III
  • Lupus Nephritis - WHO Class IV
  • Refractory Systemic Lupus Erythematosus
  • SLE

Browse trials for

Keywords

  • SLE
  • Lupus
  • Lupus Nephritis
  • AlloNK
04

In context

Lupus Nephritis Reclassified

343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.

This study's planned enrollment of 51 is close to the median of 48 across 243 interventional studies indexed under Lupus Nephritis.

Browse Lupus Nephritis studies →

Lead sponsor

Artiva Biotherapeutics, Inc. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Compared within Lupus Nephritis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lupus Erythematosus, Systemic. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria for all subjects (Lupus Nephritis or SLE)

  • Diagnosis of SLE according to the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) Classification Criteria
  • Subjects must have had an inadequate response with at least two prior lines of standard of care (SoC) treatment.

Inclusion Criteria for LN:

  • Adult subjects with lupus nephritis Class III or IV (with or without the presence of Class V)
  • Evidence of active disease on renal .
  • All subjects are required to receive adequate concomitant antihypertensive and antiproteinuric therapy with blockade of the renin-angiotensin system

Inclusion Criteria for SLE:

  • Total systemic lupus erythematosus disease activity index (SLEDAI-2K score) ≥ 8, and clinical SLEDAI-2K ≥ 4.
  • British Isles Lupus Assessment Group 2004 (BILAG-2004) activity score of A in ≥ 1 organ, or a BILAG-2004 activity score of B in ≥ 2 organs.
  • Subjects have failed at least two conventional therapies

Exclusion Criteria:

  • Known past or current
  • Clinical evidence of significant unstable or uncontrolled acute or chronic diseases not due to SLE
  • Subjects with known active viral infections
  • Severe active CNS Lupus
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
51 participants (estimated)

Study arms

  • Experimental
    Phase 1: Dose confirmation of AB-101 as Monotherapy

    Drug: AB-101 · Drug: Cyclophosphamide · Drug: Fludarabine

  • Experimental
    Phase 1: Dose confirmation of AB-101 plus Obinutuzumab combination

    Drug: AB-101 · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Obinutuzumab

  • Experimental
    Phase 1: Dose confirmation of AB-101 plus Rituximab combination

    Drug: AB-101 · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Rituximab

Interventions

07

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events

    Incidence, severity and causality of adverse events and serious adverse events

    Time frame: From the time of consent through 104 weeks after initiation of study treatment

  2. AB-101 Clinical Activity

    Determined by Overall Response Rate in subjects with lupus nephritis and refractory systemic lupus erythematosus

    Time frame: From the time of first dose through 104 weeks after initiation of study treatment

08

Study locations

9 sites
  • Artiva Investigational Site Birmingham
    Birmingham, Alabama 35249, United States
  • Artiva Investigational Site Tucson
    Tucson, Arizona 85724, United States
  • Artiva Investigational Site San Diego
    San Diego, California 92121, United States
  • Artiva Investigational Site Aventura
    Aventura, Florida 33180, United States
  • Artiva Investigational Site Plantation
    Plantation, Florida 33324, United States
  • Artiva Investigational Site Iowa
    Iowa City, Iowa 52242, United States
  • Artiva Investigational Site Charlotte
    Charlotte, North Carolina 28625, United States
  • Artiva Investigational Site Mesquite
    Mesquite, Texas 75150, United States
  • Artiva Investigational Site Woodlands
    The Woodlands, Texas 77382, United States
09

References and documents

Individual participant data

Plan to share: No — AlloNK is early in clinical development, next steps will be based on the progress of our data.

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Aug 2027, 40 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2024
First posted
Feb 20, 2024
StartActual
Apr 3, 2024
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Dec 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06265220
Lead sponsor
Artiva Biotherapeutics, Inc.
Responsible party
Sponsor
First posted
Feb 20, 2024
Start date
Apr 3, 2024
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Dec 10, 2025

Study contacts

Michael Saddekni, M.D., PgDip, BCMAS
study director · Artiva Biotherapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AB-101

Start the discussion